3-(3-(Trifluoromethyl)phenyl)propanoic acid | CAS:585-50-2

We serve 3-(3-(Trifluoromethyl)phenyl)propanoic acid CAS:585-50-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
3-(3-(Trifluoromethyl)phenyl)propanoic acid

CAS No: 585-50-2
Product Name: 3-(3-(Trifluoromethyl)phenyl)propanoic acid
Other Name:
3-(3-(Trifluoromethyl)phenyl)propanoic acid
3-(Trifluoromethyl)benzenepropanoic acid
3-(Trifluoromethyl)hydrocinnamic acid
 
Density: 1.3±0.1 g/cm3
Boiling Point: 268.7±35.0 °C at 760 mmHg
Molecular Formula: C10H9F3O2
Molecular Weight: 218.173
Flash Point: 116.3±25.9 °C
Exact Mass: 218.055466
PSA: 37.30000
LogP: 2.41
Vapour Pressure: 0.0±0.6 mmHg at 25°C
Index of Refraction: 1.475
 
Specification
Appearance: Yellow liquid
Assay: ≥99.0%
Water: ≤0.50%
 
Application
Cinacalcet Intermediate.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.



Contact us for information like 3-(3-(Trifluoromethyl)phenyl)propanoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-(Trifluoromethyl)hydrocinnamic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-(3-(Trifluoromethyl)phenyl)propanoic acid Use and application,3-(Trifluoromethyl)hydrocinnamic acid technical grade,usp/ep/jp grade.


Related News: The man recently traveled to Wuhan, China, and sought medical care soon after his return to Massachusetts.4-Chlorobenzophenone manufacturer For example, an active ingredient to relieve pain is included in a painkiller.2-Bromophenol supplier Optimize the reaction and improve the production process to reduce the production cost. At the same time, strengthen the determination and analysis of impurities to improve product quality.3-bromo-5-methylpyridine vendor Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).Over the past few days, there’s been a question dominating Chinese social media: Could a traditional Chinese medicine help fight the Wuhan coronavirus?